By Abigail Townsend
Date: Friday 16 Jan 2026
(Sharecast News) - Shares in Novo Nordisk sparked on Friday, after the UK health authority approved higher doses of the Danish firm's blockbuster weight-loss treatment Wegovy.
Currently, doctors are unable to prescribe more than 2.4 milligrams of the jab a week for patients with obesity.
However, the Medicines and Healthcare...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news